Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study (Q46414306)
scientific article published in August 2008
Language:
(P31) (Q13442814)
(P50) (Q108298727)
(P304) 646-655
(P407) (Q1860)
(P433) 9639
(P478) 372
(P577) Friday, August 1, 2008
(P921) (Q181600)
(Q422585)
(Q422618)
(Q155954)
(Q423467)
(Q422604)
(Q3836750)
(Q39053473)
(P1104) 10
(P1433) (Q939416)
(P1476) "Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study" (language: en)
(P2093) Jaime Andrade-Villanueva
Juan Echevarria
Ploenchan Chetchotisakd
Jorge Corral
Neal David
Graeme Moyle
Marco Mancini
Lisa Percival
Rong Yang
Alexandra Thiry
Donnie McGrath
CASTLE Study Team
(P2860) (Q30482995)
(Q36653838)
(Q34631629)
(Q50105738)
(Q36831639)
(Q43840888)
(Q57181081)
(Q44662157)
(Q51943315)
(Q36304804)
(Q36765802)
(Q28344472)
(Q46973541)
(Q46435678)
(Q46851728)
(Q33933318)
(Q41752733)
(Q28256092)
(Q46492574)
(Q44951046)
(Q35913181)
(Q61790672)
(Q57117642)
(Q39563727)
(Q46562126)
other details
description scientific article published in August 2008

External Links